JPWO2023066941A5 - - Google Patents
Info
- Publication number
- JPWO2023066941A5 JPWO2023066941A5 JP2024523525A JP2024523525A JPWO2023066941A5 JP WO2023066941 A5 JPWO2023066941 A5 JP WO2023066941A5 JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024523525 A JP2024523525 A JP 2024523525A JP WO2023066941 A5 JPWO2023066941 A5 JP WO2023066941A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- solution
- powder
- ray diffraction
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257073P | 2021-10-18 | 2021-10-18 | |
| US63/257,073 | 2021-10-18 | ||
| PCT/EP2022/078989 WO2023066941A1 (en) | 2021-10-18 | 2022-10-18 | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540922A JP2024540922A (ja) | 2024-11-06 |
| JPWO2023066941A5 true JPWO2023066941A5 (https=) | 2025-10-27 |
| JP2024540922A5 JP2024540922A5 (https=) | 2025-10-27 |
Family
ID=84359608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523525A Pending JP2024540922A (ja) | 2021-10-18 | 2022-10-18 | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250066382A1 (https=) |
| EP (1) | EP4419530A1 (https=) |
| JP (1) | JP2024540922A (https=) |
| CN (1) | CN118451082A (https=) |
| WO (1) | WO2023066941A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7300935B2 (en) | 2003-01-29 | 2007-11-27 | Takeda Pharmaceutical Company | Thienopyrimidine compounds and use thereof |
| AR092707A1 (es) | 2012-09-28 | 2015-04-29 | Takeda Pharmaceuticals Co | Metodo de produccion de derivado de tienopirimidina |
| TWI744224B (zh) | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| MA46361A (fr) | 2016-09-30 | 2021-03-31 | Myovant Sciences Gmbh | Traitement du cancer de la prostate |
| US11306104B2 (en) * | 2018-03-14 | 2022-04-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of Relugolix |
| WO2021069700A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
-
2022
- 2022-10-18 JP JP2024523525A patent/JP2024540922A/ja active Pending
- 2022-10-18 WO PCT/EP2022/078989 patent/WO2023066941A1/en not_active Ceased
- 2022-10-18 EP EP22805826.9A patent/EP4419530A1/en active Pending
- 2022-10-18 CN CN202280069988.XA patent/CN118451082A/zh active Pending
-
2024
- 2024-04-16 US US18/636,642 patent/US20250066382A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI823911B (zh) | 製備方法 | |
| ES2604542T3 (es) | Arilamidas con sustitución tetrazol | |
| JP4740115B2 (ja) | 置換ピラゾール | |
| US5629331A (en) | Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof | |
| HUP0200139A2 (en) | 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists, process for their preparation and pharmaceutical compositions containing them | |
| JP2008514642A5 (https=) | ||
| WO2008087529A1 (en) | Nicotinic acetylcholine receptor modulators | |
| JP2017141274A (ja) | ピロール誘導体の結晶 | |
| CN112409293B (zh) | 苯并噻嗪酮化合物及其制备方法与作为抗结核药物的应用 | |
| AU2004228121B2 (en) | 1,3,4-substituted pyrazoles for use as 5-HT receptor antagonists in the treatment of psychoses and neurological disorders | |
| JP2013542255A (ja) | ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素 | |
| JPH06508370A (ja) | アンジオテンシン２拮抗活性を有する４−（１ｈ−ピロール−１−イル）イミダゾール | |
| SK492001A3 (en) | Biphenyl derivatives | |
| AU2004228119B2 (en) | Pyrazole compounds | |
| JPS5989679A (ja) | ピラゾロ〔３，４−ｂ〕ピリジン誘導体類およびそれらの製造法 | |
| JP2009506008A (ja) | ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法 | |
| JP4385414B2 (ja) | アミド若しくはアミン誘導体 | |
| JPWO2023066941A5 (https=) | ||
| WO2007067875A2 (en) | Pyridinyl sulfonamide modulators of chemokine receptors | |
| JPWO2021069700A5 (https=) | ||
| JPWO2021069711A5 (https=) | ||
| JP7168245B2 (ja) | 三環式化合物 | |
| JP4740117B2 (ja) | 置換ピラゾール化合物 | |
| JPWO2021150723A5 (https=) | ||
| TWI781345B (zh) | Ｂａｒｉｃｉｔｉｎｉｂ的結晶型與其製備方法 |